News & Updates

On April 15, 2023, ZP Therapeutics held a scientific symposium entitled Taking Hope Further in HR+, HER2- Breast Cancer at the EDSA Shangri-La Hotel in response to the alarming trend of breast cancer being the most common type of cancer in the country, and to formally launch a new treatment option for breast cancer: Abemaciclib (Yulareb®).

In the year 2020, 27,163 new cases of breast cancer were diagnosed in the Philippines and breast cancer accounted for 17.7% of all cancer cases, making it the most common type of cancer in the country.¹

On April 15, 2023, ZP Therapeutics held a scientific symposium entitled Taking Hope Further in HR+, HER2- Breast Cancer at the EDSA Shangri-La Hotel in response to this alarming trend, and to formally launch a new treatment option for breast cancer: Abemaciclib (Yulareb®). The event gathered over 100 industry experts and oncologists from across the country.

Innovation in Breast Cancer treatment

In 2020, cases of breast cancer breached 2 million,¹ making it the most frequently diagnosed cancer in women worldwide. The increase in cases was attributed to lifestyle changes and better screening tools. Survival in the present day still heavily depends on staging and the molecular subtype. Molecular subtypes have provided breakthrough insights into new treatment strategies over the years and management have continued to evolve as more about the disease is understood.

During the Philippine Society of Medical Oncology (PSMO) 36th annual convention, women’s health was once again highlighted in the lecture “Reimagine the Future of Breast Cancer.” Dr Josephine Tolentino, Dr See Hui Ti, Dr Ellie May Villegas and Ms Aileen Antolin shared their insights during the session which was moderated by Dr Pamela Padtu.

EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute heart failure

Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.

GLP-1 RA Diabetes Mellitus Type 2 Diabetes Management Dulaglutide

Product Highlight - ACTRANEX

Tranexamic acid 100 mg/ml soln for inj 

Product Highlight - MEPRESONE 40

Methylprednisolone 40 mg powd for inj

Product Highlight - ROSUZET

Ezetimibe, rosuvastatin 10 mg/10 mg FC tab

Product Highlight - PRECEDEX PREMIX

Dexmedetomidine in 0.9% w/v sodium chloride 4 mcg/mL soln for IV infusion

Product Highlight - MISTACOR

Telmisartan 40 mg and 80 mg tab

Product-Highlight-VARICURE

Diosmin + hesperidin 450 mg/50 mg FC tab